Jeffrey M Witkin

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of rats
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 163:488-94. 2002
  2. doi request reprint The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors
    J M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    J Pharmacol Exp Ther 326:930-8. 2008
  3. doi request reprint The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence
    Jeffrey M Witkin
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA Electronic address
    Pharmacol Ther 141:283-99. 2014
  4. ncbi request reprint mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice
    S D Gleason
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, USA
    CNS Neurol Disord Drug Targets 12:554-66. 2013
  5. ncbi request reprint Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin
    Jeffrey M Witkin
    Psychiatry Drug Discovery, Lilly Research Labs, Indianapolis, IN 46285 0510, USA
    CNS Neurol Disord Drug Targets 12:498-505. 2013
  6. ncbi request reprint Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy
    Jeffrey M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Indianapolis, IN 46285 0510, USA
    CNS Neurol Disord Drug Targets 12:487-97. 2013
  7. ncbi request reprint A rapid punishment procedure for detection of anxiolytic compounds in mice
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 172:52-7. 2004
  8. ncbi request reprint Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]
    J M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    J Pharmacol Exp Ther 308:957-64. 2004
  9. ncbi request reprint NAALADase (GCP II) inhibition prevents cocaine-kindled seizures
    Jeffrey M Witkin
    Drug Development Group, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
    Neuropharmacology 43:348-56. 2002
  10. ncbi request reprint Metabotropic glutamate receptors in the control of mood disorders
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    CNS Neurol Disord Drug Targets 6:87-100. 2007

Collaborators

Detail Information

Publications58

  1. ncbi request reprint Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of rats
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 163:488-94. 2002
    ..Nonetheless, the necessary and sufficient conditions for the anxiolytic-like activity in this animal model have not been fully delineated...
  2. doi request reprint The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors
    J M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    J Pharmacol Exp Ther 326:930-8. 2008
    ....
  3. doi request reprint The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence
    Jeffrey M Witkin
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA Electronic address
    Pharmacol Ther 141:283-99. 2014
    ..The discovery of PET ligands for NOP receptors, combined with the pharmacological tools and burgeoning preclinical data set discussed here bodes well for a rapid advancement of clinical understanding and potential therapeutic benefit. ..
  4. ncbi request reprint mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice
    S D Gleason
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, USA
    CNS Neurol Disord Drug Targets 12:554-66. 2013
    ..In turn, efficacy-related data in the preclinical laboratory can help to set expectations of therapeutic potential and dosing in humans...
  5. ncbi request reprint Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin
    Jeffrey M Witkin
    Psychiatry Drug Discovery, Lilly Research Labs, Indianapolis, IN 46285 0510, USA
    CNS Neurol Disord Drug Targets 12:498-505. 2013
    ..The scientific and patient communities await the full scale clinical evaluation of a sufficiently bioavailable curcumin analog in major depressive disorder. ..
  6. ncbi request reprint Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy
    Jeffrey M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Indianapolis, IN 46285 0510, USA
    CNS Neurol Disord Drug Targets 12:487-97. 2013
    ..Although multiple approaches to this problem are being examined, a solution to the bioavailability issue will be needed to ensure appropriate tissue exposures of curcumin in clinical investigation. Progress in this regard is underway. ..
  7. ncbi request reprint A rapid punishment procedure for detection of anxiolytic compounds in mice
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 172:52-7. 2004
    ..The use of mice in these tests has been limited, but the utility of this species in drug discovery and for neurobiological inquiry would benefit from a rapid, reliable method...
  8. ncbi request reprint Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]
    J M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    J Pharmacol Exp Ther 308:957-64. 2004
    ..Together, these findings suggest that the prevention of cocaine convulsions and lethality by (+)-PD 128,907 may be due to D(3) receptor-mediated events...
  9. ncbi request reprint NAALADase (GCP II) inhibition prevents cocaine-kindled seizures
    Jeffrey M Witkin
    Drug Development Group, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
    Neuropharmacology 43:348-56. 2002
    ..Similarly, acutely-administered 2-PMPA did not block cocaine seizures in fully-kindled mice. NAALADase inhibition thus provides a novel means of attenuating the development of cocaine seizure kindling...
  10. ncbi request reprint Metabotropic glutamate receptors in the control of mood disorders
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    CNS Neurol Disord Drug Targets 6:87-100. 2007
    ....
  11. ncbi request reprint Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system
    J M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Pharmacol Ther 103:1-20. 2004
    ..H(3) receptor antagonists may also have therapeutic value in the management of obesity, pain, sleep disorders, schizophrenia, and attention deficit hyperactivity disorder...
  12. ncbi request reprint A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
    Jeffrey M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Trends Pharmacol Sci 26:609-17. 2005
    ..Thus, CB1 receptor antagonism might constitute an integrated pharmacotherapeutic approach that impacts the affective, cognitive, appetitive and motivational neuronal networks involved in mood disorders...
  13. ncbi request reprint A role for cannabinoid CB1 receptors in mood and anxiety disorders
    J M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285 0510, USA
    Behav Pharmacol 16:315-31. 2005
    ....
  14. ncbi request reprint Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds
    Jeffrey M Witkin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Epilepsy Res 75:39-45. 2007
    ..In addition, the data suggest that the lower thresholds for seizures produced by diverse mechanisms should be taken into account when interpreting other aspects of the phenotype and behavioral pharmacology of this mouse...
  15. doi request reprint Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression
    Donald R Gehlert
    Neuroscience and Endocrine Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 329:429-38. 2009
    ..Thus, GW803430 produces robust antiobesity and antidepressant-like effects in rats and mice at doses that compete for central MCHR1 in vivo. As such, MCHR1 should be considered as a promising target for future drug discovery efforts...
  16. ncbi request reprint In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
    Linda M Rorick-Kehn
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 193:121-36. 2007
    ....
  17. ncbi request reprint In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders
    Andrew Alt
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 185:240-7. 2006
    ..Although convergent evidence exists for a role of glutamate in the regulation of anxiety, the involvement of specific glutamate receptor subtypes has yet to be defined...
  18. pmc The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
    Eleni T Tzavara
    Eli Lilly and Company, Lilly Corporate Center, DC0510, Neuroscience Discovery Research, Indianapolis, IN 46285 0510, USA
    Br J Pharmacol 138:544-53. 2003
    ....
  19. ncbi request reprint Anxiolytic-like effects through a GLUK5 kainate receptor mechanism
    Andrew Alt
    Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Neuropharmacology 52:1482-7. 2007
    ..The selective targeting of kainate receptors with an antagonist could therefore be a novel pharmacological mechanism to treat anxiety disorders...
  20. ncbi request reprint Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, MSC 1408, Building 10, Room 5N250, Bethesda, MD 20892 1408, USA
    Eur J Pharmacol 494:183-9. 2004
    ..e., benzodiazepines and barbiturates), suggesting the involvement of non-GABAergic mechanisms in the effects produced by chlormethiazole...
  21. ncbi request reprint Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice
    Xia Li
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 0510, USA
    J Pharmacol Exp Ther 319:254-9. 2006
    ..This mechanism may not only provide a novel approach to the therapeutic management of depressive disorders but also may be useful in the augmentation of effects of traditional antidepressant agents...
  22. doi request reprint mGlu5 receptor deletion reduces relapse to food-seeking and prevents the anti-relapse effects of mGlu5 receptor blockade in mice
    William J A Eiler
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Life Sci 89:862-7. 2011
    ..However, the role of mGlu5 receptors in relapse to food seeking behavior has not been explored extensively and has not been scrutinized using receptor null mice...
  23. ncbi request reprint Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan
    Agustin Zapata
    Drug Development Group, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Pharmacol Biochem Behav 74:313-23. 2003
    ..These findings point to potentially novel pharmacological strategies for blocking cocaine stimulant and toxic effects...
  24. pmc Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain
    Rafal M Kaminski
    Drug Development Group, Behavioral Neuroscience Branch, National Institute on Drug Abuse, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Neurochem Res 36:146-52. 2011
    ..These data suggest that enhancement of depolarization stimulated glutamate release may be one of the mechanisms underlying the development of increased seizure susceptibility after cocaine kindling...
  25. ncbi request reprint Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling
    Rafal M Kaminski
    Integrative Neuroscience Section, Behavioral Neuroscience Branch, NIH NIDA Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Neuropharmacology 52:895-903. 2007
    ....
  26. pmc Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures
    Rafal M Kaminski
    Integrative Neuroscience Section, NIDA IRP, Baltimore, MD, USA
    Neurosci Lett 382:51-5. 2005
    ..For all drugs tested, the response of NET-HT mice was always intermediate. These data provide further support for a role of endogenous NE in the control of seizure susceptibility...
  27. doi request reprint Animal models of obsessive-compulsive disorder
    Jeffrey M Witkin
    Psychiatric Drug Discovery, Neuroscience Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Curr Protoc Neurosci . 2008
    ..The present methods might therefore provide one piece of in vivo information for the discovery of novel chemical treatment solutions for the symptoms of OCD...
  28. doi request reprint mGlu5 receptor deletion does not confer seizure protection to mice
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Life Sci 83:377-80. 2008
    ..The present findings do not support the idea that mGlu5 receptors play as important a role in seizure control as previously speculated...
  29. ncbi request reprint A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats
    Scott D Gleason
    Neuroscience Discovery Research, The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Pharmacol Biochem Behav 87:380-5. 2007
    ..Parametric variation under the Vogel conflict test may be useful in comparing the efficacy of novel approaches to the treatment of anxiety disorders...
  30. doi request reprint N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link betw
    Matthew J Fell
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 336:165-77. 2011
    ..In addition, we provide evidence that sleep EEG and CSF t-MeHA might function as viable biomarker approaches to facilitate the translational development of THIIC and other mGlu2 potentiators...
  31. ncbi request reprint Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice
    Daniel G Smith
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 31:1135-45. 2006
    ..Distinct behavioral, physiological, and neurochemical stress, and anxiety-related responses were selectively modulated by the MCHR1, and these actions may involve corticolimbic regulation of stress responsivity and anxiety...
  32. ncbi request reprint Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses
    A Zapata
    Integrative Neuroscience Unit, Behavioral Neuroscience Branch, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Neuropharmacology 41:351-9. 2001
    ..We conclude that the activation of the D3 receptor decreases extracellular dopamine levels and that, at sufficiently low doses, the effects of (+)-PD 128907 on extracellular dopamine are selectively mediated by the D3 receptor...
  33. ncbi request reprint Enhancement of antidepressant potency by a potentiator of AMPA receptors
    Xia Li
    Neuroscience Discovery Research, Eli Lilly and Co, Lilly Research Laboratories, Corporate Center, Indianapolis, Indiana, USA
    Cell Mol Neurobiol 23:419-30. 2003
    ....
  34. ncbi request reprint Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying
    Xia Li
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Life Sci 78:1933-9. 2006
    ....
  35. ncbi request reprint Pharmacological modulation of GABA(B) receptors affects cocaine-induced seizures in mice
    Maciej Gasior
    Drug Development Group, Behavioral Neuroscience Branch, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 174:211-9. 2004
    ..Previous data have demonstrated that the convulsant effects of cocaine can be modulated by compounds that increase levels of endogenous gamma-aminobutyric acid (GABA) or that directly stimulate GABA(A) receptors...
  36. doi request reprint Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats
    Scott D Gleason
    Psychiatric Disease Group, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 0510, USA
    Behav Pharmacol 22:531-9. 2011
    ..Therefore, the prominent in-vivo agonist activity of DHX at both D(1) receptors and D(2)/D(3) receptors should be considered while making predictions of effects in humans...
  37. ncbi request reprint AMPA receptor potentiators: application for depression and Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
    Curr Drug Targets 8:603-20. 2007
    ..The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease...
  38. ncbi request reprint Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393
    S D Gleason
    Neuroscience Discovery Research, The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis 46285 0510, USA
    Behav Pharmacol 15:85-9. 2004
    ..Thus, consistent with their D1 receptor pharmacology, the full D1-receptor agonists substituted completely for the discriminative stimulus of SKF 38393...
  39. ncbi request reprint AMPA receptor potentiators as novel antidepressants
    A Alt
    Eli Lilly and Company, Neuroscience Discovery Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Curr Pharm Des 11:1511-27. 2005
    ..Although these effects are also produced by traditional antidepressants, AMPA receptor potentiators appear to produce their effects through a novel mechanism...
  40. ncbi request reprint AMPA receptors in the therapeutic management of depression
    D Bleakman
    Eli Lilly and Company, Neuroscience Discovery Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    CNS Neurol Disord Drug Targets 6:117-26. 2007
    ..Combined, these data suggest that AMPA receptors may be in a key position to regulate mood disorders, and that compounds which target AMPA receptors may prove useful in the clinical management of depression...
  41. doi request reprint LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
    Linda M Rorick-Kehn
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA Electronic address
    Neuropharmacology 77:131-44. 2014
    ..LY2456302 is a centrally-penetrant, potent, kappa-selective antagonist with pharmacokinetic properties favorable for clinical development and activity in animal models predictive of efficacy in mood and addictive disorders...
  42. ncbi request reprint Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice
    Rafal M Kaminski
    NIDA Addiction Research Center, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Eur J Pharmacol 474:217-22. 2003
    ..These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse...
  43. ncbi request reprint Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine
    Scott D Gleason
    Psychiatric Drug Discovery, Neuroscience Discovery Research, The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 186:25-31. 2006
    ..To more fully characterize the discriminative stimulus properties of DHX, we trained rats to discriminate DHX (3 mg/kg, i.p.) from vehicle...
  44. doi request reprint New approaches to the pharmacological management of major depressive disorder
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Adv Pharmacol 57:347-79. 2009
    ..Accumulating evidence supports the idea that amplification of AMPA receptor function is a critical link in the transduction processes involved antidepressant effects...
  45. ncbi request reprint A role for AMPA receptors in mood disorders
    Andrew Alt
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0501, USA
    Biochem Pharmacol 71:1273-88. 2006
    ..Thus, AMPA receptor potentiation might be a general mechanism through which the clinical outcome of antidepressant efficacy is achieved...
  46. ncbi request reprint Caffeine potentiates the discriminative-stimulus effects of nicotine in rats
    Maciej Gasior
    National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 162:385-95. 2002
    ..Caffeine and nicotine are the main psychoactive ingredients of coffee and tobacco, respectively, with a high frequency of concurrent use in humans...
  47. ncbi request reprint Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine
    J M Witkin
    Drug Development Group and Integrative Neuroscience Unit Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 288:1298-310. 1999
    ..Taken together, the present findings indicate that sydnocarb has psychomotor stimulant effects that are shared by methamphetamine while demonstrating a reduced behavioral toxicity...
  48. ncbi request reprint Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine
    J M Witkin
    Drug Development Group, Behavioral Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 289:703-11. 1999
    ..Given the literature suggesting a role for these drugs in other areas of drug abuse treatments, NMDA receptor antagonists sit in a unique position as potential therapeutic candidates...
  49. ncbi request reprint Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures
    M Gasior
    Drug Development Group, Behavioral Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 290:1148-56. 1999
    ..Overall, this study provides the first description of the effectiveness of new antiepileptic drugs against experimentally induced cocaine seizures and points to several drugs that deserve clinical scrutiny for this indication...
  50. ncbi request reprint Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam
    M Gasior
    Preclinical Pharmacology Laboratory, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 282:543-53. 1997
    ..These results help to define the neuroactive steroids as a novel class of antiepileptic agents and suggest their potential in clinical practice...
  51. ncbi request reprint Effects of some antimuscarinics alone and in combination with chlordiazepoxide on punished and nonpunished behavior of rats
    J M Witkin
    Drug Development Group, NIDA Addiction Research Center, Baltimore, MD 21224
    Pharmacol Biochem Behav 39:453-6. 1991
    ..The previously reported behavioral excitatory effects of these compounds may therefore be unrelated to this pharmacological action...
  52. ncbi request reprint Lethal seizures predicted after aminophylline therapy in cocaine abusers
    M Gasior
    Drug Development Group, Behavioral Neuroscience Research Branch, National Institute on Drug Abuse, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Eur J Pharmacol 387:R15-6. 2000
    ..The present finding suggests that individuals with a history of cocaine use may be at increased risk for convulsive and lethal complications associated with the therapeutic use of aminophylline...
  53. ncbi request reprint Chlormethiazole: effectiveness against toxic effects of cocaine in mice
    M Gasior
    Drug Development Group, Behavioral Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 295:153-61. 2000
    ..The results of this study predict the potential utility of chlormethiazole for the treatment of life-threatening complications of cocaine abuse for which no specific treatment has yet been identified...
  54. ncbi request reprint Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate
    M Gasior
    Drug Development Group, Behavioral Neuroscience Research Branch, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Neuropharmacology 39:1184-96. 2000
    ..Taken together, the results of the present study add to accumulating evidence of the unique anticonvulsive/behavioral profile of neuroactive steroids...
  55. pmc Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)
    Per Svenningsson
    Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:3182-7. 2002
    ..These chronic changes may be relevant to the delayed onset of therapeutic efficacy of fluoxetine...
  56. ncbi request reprint Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation
    Per Svenningsson
    Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021, USA
    J Neurosci 27:4201-9. 2007
    ..These findings also indicate that selective 5-HT6 receptor agonists may represent a novel antidepressant drug class...
  57. pmc Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior
    Gregory T Collins
    Department of Pharmacology, 1301 MSRB III, University of Michigan Medical School, Ann Arbor, MI 48109 0632, USA
    J Pharmacol Exp Ther 314:310-9. 2005
    ..Thus, dopamine agonist-induced yawning may represent an in vivo method for selectively identifying D3 and D2 receptor-mediated activities...
  58. doi request reprint Mood disorders: regulation by metabotropic glutamate receptors
    Andrzej Pilc
    Institute of Pharmacology, Polish Academy of Sciences and Collegium Medicum, Jagiellonian University, Krakow, Poland
    Biochem Pharmacol 75:997-1006. 2008
    ....